Frontier Medicines

Finding precision medicines by understanding how small molecules interact with proteins

First Investment: 2019

For many disease-causing proteins, there are no known classical binding sites, so there’s been no way to develop small-molecule drugs to intervene. Frontier uses quantitative proteomics and machine learning to find pockets where small molecules can bind covalently, opening up formerly undruggable targets such as KRAS, a molecular switch driving many forms of cancer.

In The Media

Frontier Medicines raises $80M, enters clinic and eyes potential IPO in Q4 or early 2025

Frontier Medicines

Frontier Medicines was named one of Fierce Biotech’s Fierce 15 for the work its doing to redefine the course of debilitating diseases, using chemoproteomics and machine learning to discover new medicines.

Frontier Medicines

Explore Companies

Grove Biopharma

Putting protein-like drugs inside cells to fight cancer and neurodegeneration

Syntax Bio

Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics

Using state-of-the-art machine learning models to create custom-build protein drugs

Nilo Therapeutics

Mapping the brain-body axis to achieve proper immune balance